An upcoming FDA action date for Regeneron Pharmaceuticals' rare immune disease candidate, pozelimab, could lead to a significant boost.
https://seekingalpha.com/news/4003175-regeneron-could-see-share-price-bounce-potential-approvals
An upcoming FDA action date for Regeneron Pharmaceuticals' rare immune disease candidate, pozelimab, could lead to a significant boost.
https://seekingalpha.com/news/4003175-regeneron-could-see-share-price-bounce-potential-approvals
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.